These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

325 related items for PubMed ID: 27753529

  • 1. Cyclin G2 promotes cell cycle arrest in breast cancer cells responding to fulvestrant and metformin and correlates with patient survival.
    Zimmermann M, Arachchige-Don AP, Donaldson MS, Patriarchi T, Horne MC.
    Cell Cycle; 2016 Dec; 15(23):3278-3295. PubMed ID: 27753529
    [Abstract] [Full Text] [Related]

  • 2. Elevated cyclin G2 expression intersects with DNA damage checkpoint signaling and is required for a potent G2/M checkpoint arrest response to doxorubicin.
    Zimmermann M, Arachchige-Don AS, Donaldson MS, Dallapiazza RF, Cowan CE, Horne MC.
    J Biol Chem; 2012 Jun 29; 287(27):22838-53. PubMed ID: 22589537
    [Abstract] [Full Text] [Related]

  • 3. Roles of human epidermal growth factor receptor 2, c-jun NH2-terminal kinase, phosphoinositide 3-kinase, and p70 S6 kinase pathways in regulation of cyclin G2 expression in human breast cancer cells.
    Le XF, Arachchige-Don AS, Mao W, Horne MC, Bast RC.
    Mol Cancer Ther; 2007 Nov 29; 6(11):2843-57. PubMed ID: 18025271
    [Abstract] [Full Text] [Related]

  • 4. AKT Antagonist AZD5363 Influences Estrogen Receptor Function in Endocrine-Resistant Breast Cancer and Synergizes with Fulvestrant (ICI182780) In Vivo.
    Ribas R, Pancholi S, Guest SK, Marangoni E, Gao Q, Thuleau A, Simigdala N, Polanska UM, Campbell H, Rani A, Liccardi G, Johnston S, Davies BR, Dowsett M, Martin LA.
    Mol Cancer Ther; 2015 Sep 29; 14(9):2035-48. PubMed ID: 26116361
    [Abstract] [Full Text] [Related]

  • 5. Elevated insulin-like growth factor 1 receptor signaling induces antiestrogen resistance through the MAPK/ERK and PI3K/Akt signaling routes.
    Zhang Y, Moerkens M, Ramaiahgari S, de Bont H, Price L, Meerman J, van de Water B.
    Breast Cancer Res; 2011 May 19; 13(3):R52. PubMed ID: 21595894
    [Abstract] [Full Text] [Related]

  • 6. CSF-1 activates MAPK-dependent and p53-independent pathways to induce growth arrest of hormone-dependent human breast cancer cells.
    Lee AW, Nambirajan S, Moffat JG.
    Oncogene; 1999 Dec 09; 18(52):7477-94. PubMed ID: 10602507
    [Abstract] [Full Text] [Related]

  • 7. Binding of anterior gradient 2 and estrogen receptor-α: Dual critical roles in enhancing fulvestrant resistance and IGF-1-induced tumorigenesis of breast cancer.
    Li Z, Zhu Q, Chen H, Hu L, Negi H, Zheng Y, Ahmed Y, Wu Z, Li D.
    Cancer Lett; 2016 Jul 10; 377(1):32-43. PubMed ID: 27063095
    [Abstract] [Full Text] [Related]

  • 8. Recruitment of cyclin G2 to promyelocytic leukemia nuclear bodies promotes dephosphorylation of γH2AX following treatment with ionizing radiation.
    Naito Y, Yabuta N, Sato J, Ohno S, Sakata M, Kasama T, Ikawa M, Nojima H.
    Cell Cycle; 2013 Jun 01; 12(11):1773-84. PubMed ID: 23656780
    [Abstract] [Full Text] [Related]

  • 9. Benzopyran derivative CDRI-85/287 induces G2-M arrest in estrogen receptor-positive breast cancer cells via modulation of estrogen receptors α- and β-mediated signaling, in parallel to EGFR signaling and suppresses the growth of tumor xenograft.
    Saxena R, Fatima I, Chandra V, Blesson CS, Kharkwal G, Hussain MK, Hajela K, Roy BG, Dwivedi A.
    Steroids; 2013 Nov 01; 78(11):1071-86. PubMed ID: 23891847
    [Abstract] [Full Text] [Related]

  • 10. Estrogen utilization of IGF-1-R and EGF-R to signal in breast cancer cells.
    Song RX, Chen Y, Zhang Z, Bao Y, Yue W, Wang JP, Fan P, Santen RJ.
    J Steroid Biochem Mol Biol; 2010 Feb 28; 118(4-5):219-30. PubMed ID: 19815064
    [Abstract] [Full Text] [Related]

  • 11. Activated Raf-1 causes growth arrest in human small cell lung cancer cells.
    Ravi RK, Weber E, McMahon M, Williams JR, Baylin S, Mal A, Harter ML, Dillehay LE, Claudio PP, Giordano A, Nelkin BD, Mabry M.
    J Clin Invest; 1998 Jan 01; 101(1):153-9. PubMed ID: 9421477
    [Abstract] [Full Text] [Related]

  • 12. Fulvestrant regulates epidermal growth factor (EGF) family ligands to activate EGF receptor (EGFR) signaling in breast cancer cells.
    Zhang X, Diaz MR, Yee D.
    Breast Cancer Res Treat; 2013 Jun 01; 139(2):351-60. PubMed ID: 23686416
    [Abstract] [Full Text] [Related]

  • 13. Estrogen action via the G protein-coupled receptor, GPR30: stimulation of adenylyl cyclase and cAMP-mediated attenuation of the epidermal growth factor receptor-to-MAPK signaling axis.
    Filardo EJ, Quinn JA, Frackelton AR, Bland KI.
    Mol Endocrinol; 2002 Jan 01; 16(1):70-84. PubMed ID: 11773440
    [Abstract] [Full Text] [Related]

  • 14. Src Inhibition with saracatinib reverses fulvestrant resistance in ER-positive ovarian cancer models in vitro and in vivo.
    Simpkins F, Hevia-Paez P, Sun J, Ullmer W, Gilbert CA, da Silva T, Pedram A, Levin ER, Reis IM, Rabinovich B, Azzam D, Xu XX, Ince TA, Yang JY, Verhaak RG, Lu Y, Mills GB, Slingerland JM.
    Clin Cancer Res; 2012 Nov 01; 18(21):5911-23. PubMed ID: 22896656
    [Abstract] [Full Text] [Related]

  • 15. FGFR1 Overexpression Induces Cancer Cell Stemness and Enhanced Akt/Erk-ER Signaling to Promote Palbociclib Resistance in Luminal A Breast Cancer Cells.
    Cheng Q, Ma Z, Shi Y, Parris AB, Kong L, Yang X.
    Cells; 2021 Nov 04; 10(11):. PubMed ID: 34831231
    [Abstract] [Full Text] [Related]

  • 16. Involvement of G1/S cyclins in estrogen-independent proliferation of estrogen receptor-positive breast cancer cells.
    Bindels EM, Lallemand F, Balkenende A, Verwoerd D, Michalides R.
    Oncogene; 2002 Nov 21; 21(53):8158-65. PubMed ID: 12444551
    [Abstract] [Full Text] [Related]

  • 17. Src Is a Potential Therapeutic Target in Endocrine-Resistant Breast Cancer Exhibiting Low Estrogen Receptor-Mediated Transactivation.
    Guest SK, Ribas R, Pancholi S, Nikitorowicz-Buniak J, Simigdala N, Dowsett M, Johnston SR, Martin LA.
    PLoS One; 2016 Nov 21; 11(6):e0157397. PubMed ID: 27308830
    [Abstract] [Full Text] [Related]

  • 18. Down-regulation of cyclin-dependent kinase-4 and MAPK through estrogen receptor mediated cell cycle arrest in human breast cancer induced by gold nanoparticle tagged toxin protein NKCT1.
    Bhowmik T, Gomes A.
    Chem Biol Interact; 2017 Apr 25; 268():119-128. PubMed ID: 28322778
    [Abstract] [Full Text] [Related]

  • 19. Pharmacologic inhibition of RAF-->MEK-->ERK signaling elicits pancreatic cancer cell cycle arrest through induced expression of p27Kip1.
    Gysin S, Lee SH, Dean NM, McMahon M.
    Cancer Res; 2005 Jun 01; 65(11):4870-80. PubMed ID: 15930308
    [Abstract] [Full Text] [Related]

  • 20. Alteration of Y-box binding protein-1 expression modifies the response to endocrine therapy in estrogen receptor-positive breast cancer.
    Ito T, Kamijo S, Izumi H, Kohno K, Amano J, Ito K.
    Breast Cancer Res Treat; 2012 May 01; 133(1):145-59. PubMed ID: 21863258
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.